Five or six years ago, when people talked about digitalization, they thought it was innovation. Today, if we don't go digital, it's a matter of enterprise life and death. "On September 15th, at the" Specialized, Refined, Special, and New "Entrepreneurs Forum held in Chengdu, Xu Tao, President of Meinian Health Group, said in a speech titled" Comprehensive Construction of New Models and Business Forms of Health Management in the Digital Intelligence Era ", clarifying that in today's era, digitalization The implementation and application of AI in the physical examination industry and medical health, as well as the prospect of a new ecosystem. When new technologies such as AI and AIGC become the hottest topics in 2023, Xu Tao stated that the medical examination industry has taken a lead. Whether it is IT, BD, AI technology diagnosis, or related closed-loop products, they have been widely applied in today's physical examinations and continuously strengthen the discipline construction of ultrasound, examination, imaging, and general examination. In the past two years, Meinian has continued to make efforts in AI physical examination products and closed-loop services, including AI diagnosis for stroke, brain cognition, pulmonary nodules and coronary artery AI diagnosis, breast ultrasound AI diagnosis, ultrasound AI quality control, fundus AI diagnosis, and other products, which fully reflect the innovative capabilities of the physical examination industry. "Xu Tao introduced. In 2022, Meinian Health released the market's first brain examination product, "Brain Ruijia". Through high-resolution brain volume magnetic resonance imaging, assessment of 100 brain regions and cognitive function, neuropsychological intelligence assessment, and based on a 10-year cognitive impairment disease risk model, it can reveal the potential risks of patients 5 to 10 years in advance, in order to achieve the purpose of early intervention and treatment in physical examination services. The pulmonary nodules screening product "Feijiening" is another closed-loop service product that addresses the pain points of physical examination customer needs. In the annual physical examination of Meinian, the detection rate of pulmonary nodules exceeded 50%. In order to alleviate the anxiety of those who have detected pulmonary nodules, Meinian developed a "temperature sensitive" product from the perspective of customers in 2022. For those who have detected pulmonary nodules, Meinian will further recommend screening for lung cancer tumor markers, provide remote AI film reading and remote diagnosis by tertiary doctors. Once malignant cases are detected, a first level warning will be immediately activated, Assist clients in connecting with tertiary hospitals, provide insurance solutions, and fully address medical services and payment guarantees, truly achieving closed-loop management throughout the entire process. In 2023, the company will continue to refine innovative products such as Meinian's mental health and immune cell storage. For example, AI calcification points have been established in 500 physical examination branches, with a coverage rate of over 80%, truly meeting the needs of customers in cardiopulmonary screening. The company has successively launched AI products in vascular health, immunity assessment, diabetes health management, liver health and other aspects, fully realizing the application of AI and big data before, during and after examination. The initial formation of digital layout emphasizes that digital transformation has always been a key layout in the past two years of Meinian. Now, through digitization, the company has connected the data center, built an intelligent engine, and the overall digital architecture has been preliminarily formed. In 2023, the company upgraded and launched the self-developed Bianque Physical Examination Management SAAS cloud platform, which significantly improved medical quality services and operational efficiency